Navigation Links
Novel drug discovery tool could identify promising new therapies for Parkinson's disease
Date:7/13/2009

Researchers funded by the National Institutes of Health have turned simple baker's yeast into a virtual army of medicinal chemists capable of rapidly searching for drugs to treat Parkinson's disease.

In a study published online today in Nature Chemical Biology, the researchers showed that they can rescue yeast cells from toxic levels of a protein implicated in Parkinson's disease by stimulating the cells to make very small proteins called cyclic peptides. Two of the cyclic peptides had a protective effect on the yeast cells and on neurons in an animal model of Parkinson's disease.

"This biological approach to compound development opens up an entirely new direction for drug discovery, not only for Parkinson's disease, but theoretically for any disease where key aspects of the pathology can be reproduced in yeast," says Margaret Sutherland, Ph.D., a program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS). "A key step for the future will be to identify the cellular pathways that are affected by these cyclic peptides."

The research emerged from the lab of Susan Lindquist, Ph.D., a professor of biology at the Massachusetts Institute of Technology (MIT), a member of the Whitehead Institute for Biomedical Research, and a Howard Hughes Medical Institute investigator. Dr. Lindquist is also an investigator at the Massachusetts General Hospital (MGH)/MIT Morris K. Udall Center for Excellence in Parkinson's Research, one of 14 such centers funded by NINDS to develop treatment breakthroughs for Parkinson's disease. The study received additional funding from NIH's National Institute of Environmental Health Sciences, and from the Michael J. Fox Foundation and the American Parkinson's Disease Association.

Parkinson's disease attacks cells in a part of the brain responsible for motor control and coordination. As those neurons degenerate, the disease leads to progressive deterioration of motor functio
'/>"/>

Contact: Daniel Stimson
stimsond@ninds.nih.gov
301-496-5751
NIH/National Institute of Neurological Disorders and Stroke
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novel method predicts impact of a covert anthrax release
2. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
3. Novel handheld device detects anthrax with outstanding accuracy and reliability
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
6. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
7. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
8. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
9. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
10. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
11. Biomimetic-engineering design can replace spaghetti tangle of nanotubes in novel material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Potential Blockbuster Product for High Risk Cardiovascular ... ... Calif., Jan. 7 ,Genzyme Corp. (Nasdaq: GENZ ) and Isis ... a major strategic alliance in which,Genzyme will develop and commercialize mipomersen, ...
... Jan. 7 Cephalon, Inc. (Nasdaq:,CEPH) announced today that ... at the JPMorgan Healthcare Conference are now available on ... . On Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., ... at the,Conference beginning at 2:00 p.m. Pacific Time (5 ...
... of Investment Success -, GAITHERSBURG, Md., Jan. ... of AstraZeneca plc (LSE: AZN.L, NYSE:,AZN), today announced ... will broaden its focus to include areas of ... areas of,cardiovascular and metabolic disease, pain and central ...
Cached Biology Technology:Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3
(Date:12/17/2014)... 2014 The Defense Logistics Agency is insourcing its ... counterfeit microcircuits from entering into its supply chain. ... anti-counterfeit initiative dubbed DNA marking. The capability will validate ... throughout the supply chain. The new quality control measures ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... in the most exciting and unsettling period in the ... in public. On the one hand, the ... the psychiatric diagnostic manual, DSM-V, representing the current best ... categorize the enormously complex pattern of human emotional, cognitive, ...
... University of Adelaide has shown for the first time ... greatly increasing the risk of complications for themselves and their unborn ... world, researchers from the University,s Robinson Institute compared data ... results have been published online ahead of print in the ...
... time that the blood vessels that transport blood to and ... just bodily pipelines. Arterioles and capillaries, the small vessels, actually ... blood they,re carrying. Biomedical engineers at Drexel University, who study ... how they do it. The team, which includes Drs. ...
Cached Biology News:What is the brain telling us about the diagnoses of schizophrenia and bipolar disorder? 2Smoking + asthma + pregnant = a dangerous combination 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
Request Info...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
Biology Products: